Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (6747)	1/19/1999 7:54:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Pfizer Beats Wall Street Estimates By PHIL GALEWITZ 01/19/99 AP Online NEW YORK (AP) - Viagra sales regained their vigor in the fourth quarter, helping Pfizer Inc. on Tuesday beat Wall Street earnings estimates. Excluding one-time items, Pfizer earned $711 million in the quarter, a 42 percent increase over the same period last year. Earnings per diluted share were 54 cents, beating analysts' estimates by 2 cents, according to First Call. Net profit rose 14 percent to $634 million, or 49 cents per share. Pfizer's total sales for the fourth quarter of 1998 were $3.87 billion, an increase of 26 percent over the fourth quarter of 1997. Excluding the negative effect of foreign exchange, total revenues increased by 28 percent. Higher sales of Viagra , the anti-impotence pill, were driven by the drug's introduction in Europe and South America in the fourth quarter. Perhaps more significantly, U.S. Viagra sales also jumped 10 percent to $131 million in the fourth quarter. Global Viagra sales were $236 million in the fourth quarter, still far below the $411 million in the second quarter when the drug was approved for use in the United States, but considerably higher than the $141 million in sales in the third quarter. Viagra , the fastest-selling new drug in pharmaceutical history, hit a slowdown last summer after concerns about dangerous side effects grew and several large health insurers decided not to cover the pill. Though analysts once predicted at least $1 billion in Viagra sales for last year, most said the $788 million in 1998 Viagra sales that Pfizer posted still met or exceeded their latest projections. About 200,000 U.S. doctors have written more than 7 million prescriptions for 3 million patients. Viagra is now available in 40 countries worldwide, though Pfizer is awaiting permission to sell it in Japan, the second-largest pharmaceutical market in the world. "Pfizer is very strong across the board," said David Saks, an analyst with Gruntal & Co. He stressed the company has several strong drugs, and is not reliant merely on Viagra . Indeed, Viagra is Pfizer's fifth best-selling drug, though easily the most recognized. Pfizer had three drugs bring in more than $1 billion in sales in 1998: Norvasc, a high blood pressure and angina medication; Zoloft, for depression; and Zithromax, an antibiotic. Diflucan, a drug for yeast infection, reached $916 million in sales last year. All four of the drugs saw double-digit growth in 1998. "Based on these numbers, Pfizer is poised to have a superior 1999," said Hemant Shah, a drug industry analyst with HKS & Co. in Warren, N.J. Shares of Pfizer closed at $115.87 1/2 , down 6 1/4 cents in trading on the New York Stock Exchange. For the full year, Pfizer's total sales were $13.54 billion, a 23 percent increase over 1997. Profit for 1998 was $2.63 billion, a 27 percent increase over 1997.